Twenty-six patients with surface vesical tumor receiving epirubicin are included for prophylaxis of relapse following surgical exeresis. The dosage used was 15 endovesical instillations of 50 mg in 50 cc sterile water, one instillation a week during the first month followed by once monthly to complete a year. After an average follow-up of 14 months a percentage of 19% relapses were observed with a relapse are of 1.3. Toxic events were seen in 46.1% of cases, and were almost exclusively chemical cystitis. Due to intractable vesical intolerance 5 patients were withdrawn from the study. Epirubicin was shown to be effective in reducing the relapse rate but showed a high incidence of chemical cystitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome.
PLoS One
January 2025
Glycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.
Chemical modification of naturally derived glycosaminoglycans (GAGs) expands their potential utility for applications in soft tissue repair and regenerative medicine. Here we report the preparation of a novel crosslinked chondroitin sulfate (~200 to 2000 kilodaltons) that is both soluble in aqueous solution and microfilterable. We refer to these materials as "SuperGAGs.
View Article and Find Full Text PDFIntravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette-Guérin (BCG) immunotherapy.
Int Urol Nephrol
January 2025
Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy.
Purpose: Intravesical (i) immunotherapy with Bacillus Calmette-Guérin (BCG) is the recommended treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) after complete tumor resection. Discontinuation or suspension of this therapy is often due to local side effects. Aim of the study was to evaluate the efficacy and safety of sequential intravesical instillations of combined hyaluronic acid (HA) and chondroitin sulfate (CS) in reducing local BCG toxicity and urinary symptoms.
View Article and Find Full Text PDFAnti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model.
Investig Clin Urol
January 2025
Department of Urology, Ewha Womans University College of Medicine, Seoul, Korea.
Purpose: Although the mechanism underlying interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, oxidative stress is suggested to be implicated in IC/BPS development. Sea buckthorn (SB; L.) contains several compounds with antioxidant properties.
View Article and Find Full Text PDFRetrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium.
PLoS One
January 2025
Verana Health, San Francisco, CA, United States of America.
Purpose: To evaluate prevalence and incidence rates of pigmentary maculopathy and retinopathy (PM/PR), and visual acuity (VA) changes in patients exposed to pentosan polysulfate sodium (PPS) and in patients with interstitial cystitis (IC) not exposed to PPS.
Methods: This is a retrospective cohort study (January 2015-March 2021) which included adult de-identified patients from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and Komodo Health database. Three patient cohorts were identified: two PPS-exposed patient cohorts, and Non-PPS-exposed IC patient cohort.
Urotoxicity of Cyclophosphamide: A Comparison Across Neoplastic, Autoimmune, and Transplant Indications.
Cureus
December 2024
Internal Medicine/Nephrology, Riverside Health System, Yonkers, USA.
We conducted a large-scale disproportionality analysis of the urotoxicity of cyclophosphamide (CYC) and the related drug ifosfamide (IFO) using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, with data ranging from Q4 2012 to Q2 2024. We compared the reporting odds ratio (ROR) of various urotoxicity manifestations of CYC and IFO across patient populations being treated for antineoplastic, immunosuppressive, and transplantation indications. When a wide range of urotoxicity manifestations was aggregated, we found that transplant patients had an increased relative susceptibility to CYC urotoxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!